Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.

Carette JE, Graat HC, Schagen FH, Mastenbroek DC, Rots MG, Haisma HJ, Groothuis GM, Schaap GR, Bras J, Kaspers GJ, Wuisman PI, Gerritsen WR, van Beusechem VW.

Virology. 2007 Apr 25;361(1):56-67. Epub 2006 Dec 19.

2.

Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors.

van Beusechem VW, Mastenbroek DC, van den Doel PB, Lamfers ML, Grill J, Würdinger T, Haisma HJ, Pinedo HM, Gerritsen WR.

Gene Ther. 2003 Nov;10(23):1982-91.

PMID:
14528322
3.

Cancer gene therapy with oncolytic adenoviruses.

Guse K, Hemminki A.

J BUON. 2009 Sep;14 Suppl 1:S7-15. Review.

PMID:
19785073
4.

Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.

Liu TC, Wang Y, Hallden G, Brooks G, Francis J, Lemoine NR, Kirn D.

Gene Ther. 2005 Sep;12(17):1333-46.

PMID:
15920462
5.

A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.

Hu ZB, Wu CT, Wang H, Zhang QW, Wang L, Wang RL, Lu ZZ, Wang LS.

Cancer Gene Ther. 2008 Mar;15(3):173-82. Epub 2007 Dec 21.

PMID:
18157145
6.

Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.

Guse K, Dias JD, Bauerschmitz GJ, Hakkarainen T, Aavik E, Ranki T, Pisto T, Särkioja M, Desmond RA, Kanerva A, Hemminki A.

Gene Ther. 2007 Jun;14(11):902-11. Epub 2007 Mar 22.

PMID:
17377596
7.

Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential.

Hemminki A, Wang M, Hakkarainen T, Desmond RA, Wahlfors J, Curiel DT.

Cancer Gene Ther. 2003 Aug;10(8):583-8.

PMID:
12872139
8.

Oncolytic adenoviruses - selective retargeting to tumor cells.

Mathis JM, Stoff-Khalili MA, Curiel DT.

Oncogene. 2005 Nov 21;24(52):7775-91. Review.

PMID:
16299537
9.

Targeting of adenoviral vectors through a bispecific single-chain antibody.

Haisma HJ, Grill J, Curiel DT, Hoogeland S, van Beusechem VW, Pinedo HM, Gerritsen WR.

Cancer Gene Ther. 2000 Jun;7(6):901-4.

10.

Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer.

van der Poel HG, Molenaar B, van Beusechem VW, Haisma HJ, Rodriguez R, Curiel DT, Gerritsen WR.

J Urol. 2002 Jul;168(1):266-72.

PMID:
12050554
11.
12.

Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells.

Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A.

Mol Ther. 2006 Aug;14(2):164-74. Epub 2006 Mar 31.

13.

Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.

Geoerger B, van Beusechem VW, Opolon P, Morizet J, Laudani L, Lecluse Y, Barrois M, Idema S, Grill J, Gerritsen WR, Vassal G.

J Gene Med. 2005 May;7(5):584-94.

PMID:
15651070
14.

Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.

Zhang Z, Huang Y, Newman K, Gu J, Zhang X, Wu H, Zhao M, Xianyu Z, Liu X.

Clin Cancer Res. 2009 Aug 15;15(16):5154-60. doi: 10.1158/1078-0432.CCR-09-0025. Epub 2009 Aug 11.

15.

Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody.

Würdinger T, Verheije MH, Raaben M, Bosch BJ, de Haan CA, van Beusechem VW, Rottier PJ, Gerritsen WR.

Gene Ther. 2005 Sep;12(18):1394-404.

PMID:
15843808
16.

A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.

Wang X, Su C, Cao H, Li K, Chen J, Jiang L, Zhang Q, Wu X, Jia X, Liu Y, Wang W, Liu X, Wu M, Qian Q.

Mol Cancer Ther. 2008 Jun;7(6):1598-603. doi: 10.1158/1535-7163.MCT-07-2429.

17.
18.

ReVOLT: radiation-enhanced viral oncolytic therapy.

Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR.

Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):637-46. Review.

PMID:
17011442
19.

Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.

van Beusechem VW, Grill J, Mastenbroek DC, Wickham TJ, Roelvink PW, Haisma HJ, Lamfers ML, Dirven CM, Pinedo HM, Gerritsen WR.

J Virol. 2002 Mar;76(6):2753-62.

20.

Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule.

Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT.

Cancer Res. 2001 Sep 1;61(17):6377-81.

Supplemental Content

Support Center